⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 26, 2024Alexandria Journal of MedicineOpen Access

Asprosin in nonalcoholic fatty liver disease and hypothyroidism: a case-control study

Mona Abdel-Latif Aboul-Seoud Mohamed Kamal Ghitany Ola Atef Sharaki Ahmed Alaa Abdul-Aziz Mohammed Said Sayed Shater

View Full Paper

Ask AI

Bookmark

Share

Abstract

Purpose The present study aimed to determine the serum level of asprosin, a novel glucogenic and orexigenic hormone, in NAFLD and hypothyroidism patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aboul-Seoud et al. (2024) studied this question.

synapsesocial.com/papers/68e5add7b6db643587547e65 https://doi.org/10.1080/20905068.2024.2381153

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species2024 · 15 citations
2Evaluation of NLRP3 and Asprosin Levels in Hashimoto's ThyroiditisOriginal Research · 2026
3Association of serum asprosin with metabolic dysfunction-associated fatty liver disease in older adult type 2 diabetic patients: a cross-sectional study2024 · 13 citations
4The relationship of non-alcoholic fatty liver disease in hypothyroid patientscross-sectional · 2024
5Association of Euthyroid Thyroid Hormone Levels with Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver DiseaseRetrospective Study · 2026